Fidelity SPDR Advertisement
Home > Boards > Free Zone > Health and Sciences > Biotech Values

If the progression assessments for the two metrics

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
DewDiligence Member Profile
Member Level 
Followed By 477
Posts 80,538
Boards Moderated 24
Alias Born 09/05/02
160x600 placeholder
Target again lowered its earnings outlook for the year, still reeling from data breach of its customers' credit and debit card information and slower traffic at its stores. Target also posted a 62% decline in 2Q earnings. Shares fell 1% premarket.
More Top Equities Stories Of The Day
Berkshire Hathaway Continued Investing in Media in 2Q
Skilled HealthCare, Genesis HealthCare to Merge
Tech Stocks Weaken Ahead Of H-P's Earnings
Infineon to Buy International Rectifier for $3 Billion -- 4th Update
Steve Ballmer Steps Down From Microsoft Board -- Update
U.S. Hot Stocks: Hot Stocks to Watch
Alaska Oil Tax Repeal Measure Losing--Update
Supervalu Investigating Potential Data Breach
DewDiligence Member Level  Thursday, 05/24/12 02:22:04 PM
Re: jq1234 post# 142539
Post # of 181366 
If the progression assessments for the two metrics are made on the same schedule for every patient, it shouldn’t be possible for PFS to be greater than TTP. A death in between progression assessments ought not to cause a patient to be deleted from the TTP dataset, but rather for TTP to be censored at the time of death.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist